Science Explorer Interactive view Map
Company · Boston · United States

Ziopharm Oncology (United States)

ziopharm.comROR OpenAlex
Research works
72
▼ 54% vs 2013–17
Citations
1.7k
23.7 per fractional work
Top-10% rate
3.2%
record average 16.5%
Open access
42%
world 28%

Not ranked overall: Ziopharm Oncology (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.11× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 4.73× its world share, 2 worksBiochemistry, Geneti…Immunology and Microbiology: 4.15× its world share, 0 worksImmunology and Micro…Neuroscience: 0.48× its world share, 0 worksNeuroscienceComputer Science: 0.05× its world share, 0 worksComputer ScienceEngineering: 0.14× its world share, 0 worksEngineeringEnvironmental Science: 0.11× its world share, 0 worksEnvironmental ScienceMedicine: 3.28× its world share, 4 worksMedicineNursing: 6.40× its world share, 0 worksNursing1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Nursing, 6.4×. Every wedge is a field page.

Which keywords describe research at Ziopharm Oncology (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Immunotherapy, Cancer Immunotherapy, Tumor Regression, Lymphoma, CAR T Cells, Chimeric Antigen Receptor, Gene Therapy and Cancer Therapy.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Immunotherapy15▲ 32×10 topics
  2. Cancer Immunotherapy12▲ 121×2 topics
  3. Tumor Regression12▲ 195×2 topics
  4. Lymphoma10▲ 88×2 topics
  5. CAR T Cells9▲ 297×1 topic
  6. Chimeric Antigen Receptor9▲ 297×1 topic
  7. Gene Therapy8▲ 42×3 topics
  8. AAV5▲ 108×1 topic
  9. Cancer Therapy5▲ 11×11 topics
  10. Viral Vectors5▲ 108×1 topic
  11. Innate Immunity4▲ 17×6 topics
  12. Cancer4▲ 3.9×14 topics
  13. Immunity4▲ 16×3 topics
  14. Chemotherapy4▲ 6.9×10 topics
  15. Nuclear Receptors4▲ 26×4 topics
  16. Antigen Presentation3▲ 41×1 topic
  17. Bacterial Therapy3▲ 94×1 topic
  18. Dendritic Cells3▲ 36×1 topic
  19. Tumor Targeting3▲ 31×1 topic
  20. Tumor Microenvironment3▲ 12×4 topics
  21. Prognostic Factors3▲ 8.4×8 topics
  22. Anticancer Agents2▲ 13×6 topics
  23. Glycosylation2▲ 14×3 topics
  24. Acute Promyelocytic Leukemia2▲ 105×1 topic
  25. Retinoic Acid2▲ 105×1 topic
  26. Apoptosis2▲ 7.2×5 topics
  27. Signaling2▲ 25×3 topics
  28. Transcriptional Regulation2▲ 10×6 topics
  29. Targeted Therapy2▲ 11×3 topics
  30. Biological Evaluation2▲ 19×4 topics
  31. Inhibitors2▲ 31×2 topics
  32. Monoclonal Antibodies2▲ 16×3 topics
  33. Mutation2▲ 14×2 topics
  34. Therapeutic Antibodies2▲ 17×2 topics
  35. Tumor Hypoxia2▲ 25×2 topics
  36. Heterocyclic Compounds2▲ 13×3 topics
  37. Molecular Classification2▲ 14×2 topics
  38. Resistance2▲ 18×2 topics
  39. Glioblastoma1▲ 33×1 topic
  40. Temozolomide1▲ 33×1 topic

Which research topics does Ziopharm Oncology (United States) publish most on?

By volume in 2022–2025: Medical Imaging Techniques and Applications, Neuroendocrine Tumor Research Advances, Single-cell and spatial transcriptomics and Cancer, Hypoxia, and Metabolism.

Medical Imaging Techniques and Applications: 1 fractional worksNeuroendocrine Tumor Research Advances: 1 fractional worksSingle-cell and spatial …0Single-cell and spatial transcriptomics: 0 fractional worksCancer, Hypoxia, and Met…0Cancer, Hypoxia, and Metabolism: 0 fractional worksCancer Immunotherapy and Biomarkers: 0 fractional worksLung Cancer Research Studies: 0 fractional worksPeptidase Inhibition and…0Peptidase Inhibition and Analysis: 0 fractional worksRadiopharmaceutical Chemistry and Applications: 0 fractional worksEnzyme function and inhibition: 0 fractional worksImmune cells in cancer0Immune cells in cancer: 0 fractional works
Radiology, Nuclear Medicine and ImagingEpidemiologyMolecular BiologyCancer Research2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Medical Imaging Techniques and Applications Radiology, Nuclear Medicine and Imaging 1 works
  2. 2 Neuroendocrine Tumor Research Advances Epidemiology 1 works
  3. 3 Single-cell and spatial transcriptomics Molecular Biology 0 works
  4. 4 Cancer, Hypoxia, and Metabolism Cancer Research 0 works
  5. 5 Cancer Immunotherapy and Biomarkers Oncology 0 works
  6. 6 Lung Cancer Research Studies Oncology 0 works
  7. 7 Peptidase Inhibition and Analysis Oncology 0 works
  8. 8 Radiopharmaceutical Chemistry and Applications Radiology, Nuclear Medicine and Imaging 0 works
  9. 9 Enzyme function and inhibition Molecular Biology 0 works
  10. 10 Immune cells in cancer Immunology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available42.3%not open57.7%

World: 28% of research is openly available.

with international co-authors19.0%domestic only81.0%

World: 19% is written across borders.

How has Ziopharm Oncology (United States)'s research output changed?

Output in 2018–2022 was 54% lower than in 2013–2017.

200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Boston

All research institutions in Boston

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.